Ordinary shares, par value $0.0001 per share*
- Symbol
- No trading symbol declared
- Exchange
- NASDAQ
- Classification
- COMMON
Current Report · Items 5.07 · 8-K
Structure Therapeutics Inc.
Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. On June 17, 2026, Structure Therapeutics Inc. (the “Company”) held its 2026 Annual General Meeting of Shareholders (the “Annual General Meeting”). As of April 20, 2026, the record date for the Annual General Meeting, 213,213,565 ordinary shares were outstanding and entitled to vote at the Annual General Meeting.…
Company context
Structure Therapeutics is a science-driven clinical-stage biopharmaceutical company focused on discovering and developing innovative oral small molecule treatments for chronic metabolic conditions with significant unmet medical needs. Utilizing its next generation structure-based drug discovery platform, the Company has established a robust GPCR-targeted pipeline, featuring multiple wholly-owned proprietary clinical-stage oral small molecule compounds designed to surpass the scalability limitations of traditional biologic and peptide therapies and be accessible to more people living with obesity around the world. For additional information, please visit www.structuretx.com.
Current securities
Registered securities in this filing
Structure Therapeutics Inc. · 8-K · Filed 2026-06-18
American Depositary Shares (ADSs), each representing three ordinary shares, par value $0.0001 per ordinary share
- Symbol
- GPCR
- Exchange
- NASDAQ
- Classification
- ADS
- Status
- Current
Disclosure sections
Item 5.07Item 5.07 - Submission of Matters to Vote
Item 5.07 Submission of Matters to a Vote of Security Holders.
On June 17, 2026, Structure Therapeutics Inc. (the “Company”)
held its 2026 Annual General Meeting of Shareholders (the “Annual General Meeting”). As of April 20, 2026, the record
date for the Annual General Meeting, 213,213,565 ordinary shares were outstanding and entitled to vote at the Annual General Meeting.
A summary of the matters voted upon by shareholders at the Annual General Meeting is set forth below.
Proposal 1: Election of Directors
Ted W. Love M.D., Raymond Stevens, Ph. D. and Daniel
G. Welch were elected as a Class III directors, to hold office until the 2029 Annual General Meeting of Shareholders and their successors
are duly elected and qualified, or until their earlier death, resignation or removal. The final voting results are as follows:
Name of Director Elected Votes For Votes Against Abstentions Broker Non-Votes
───────────────────────────────────────────────────────────────────────────────────────────────────────
Ted W. Love, M.D. 164,241,780 533,358 172,641 -0-
Raymond Stevens, Ph. D. 164,373,741 400,929 173,109 -0-
Daniel G. Welch 161,336,058 3,429,342 182,379 -0-
Proposal 2: Ratification of Appointment of
Independent Registered Public Accounting Firm
The Company’s shareholders ratified the
appointment by the Audit Committee of the Company’s Board of Directors of Ernst & Young LLP as the Company’s independent
registered public accounting firm for the fiscal year ending December 31, 2026. The final voting results are as follows:
Votes For Votes Against Abstentions Broker Non-Votes
──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
164,767,215 20,784 159,780 -0-
Proposal 3: Advisory vote on the compensation of the Company’s
named executive officers
On an advisory basis, the shareholders approved
the compensation of the Company’s named executive officers, as disclosed in the Company’s proxy statement for the Annual General
Meeting. The voting results are as follows:
Votes For Votes Against Abstentions Broker Non-Votes
─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
158,547,441 6,187,647 212,691 -0-